Ultragenyx Pharmaceutical Inc (RARE): prezzo delle azioni e notizie

Simboli Simboli	Prezzo	Cambio	% di cambio	Tendenza	Chiusura prec.	Apri	Alto	Basso	Volume	Cap. mercato
SIXB Materials SIXB Materials	SIXB -1,37%	1.076,52	-14,99	-1,37%	—	1.091,51	1.090,40	1.090,40	1.075,55	—	—
SIXC Communications SIXC Communications	SIXC -0,41%	607,58	-2,53	-0,41%	—	610,11	610,11	610,29	606,17	—	—
SIXE Energy SIXE Energy	SIXE +0,80%	1.247,87	+9,89	+0,80%	—	1.237,98	1.237,83	1.252,41	1.225,03	—	—
SIXI Industrials SIXI Industrials	SIXI -1,01%	1.727,04	-17,67	-1,01%	—	1.744,71	1.740,95	1.747,29	1.721,57	—	—
SIXM Financials SIXM Financials	SIXM -0,67%	635,91	-4,27	-0,67%	—	640,18	639,92	643,19	636,28	—	—
SIXR Staples SIXR Staples	SIXR -0,83%	842,55	-7,03	-0,83%	—	849,58	845,27	851,68	841,28	—	—
SIXRE Real estate SIXRE Real estate	SIXRE -0,61%	216,15	-1,33	-0,61%	—	217,48	217,48	218,16	216,22	—	—
SIXT Technology SIXT Technology	SIXT -0,12%	3.256,94	-3,75	-0,12%	—	3.260,69	3.273,36	3.287,81	3.240,78	—	—
SIXU Utilities SIXU Utilities	SIXU -0,60%	936,77	-5,68	-0,60%	—	942,45	939,39	948,80	934,04	—	—
SIXV Health care SIXV Health care	SIXV -0,55%	1.458,76	-8,04	-0,55%	—	1.466,80	1.464,70	1.467,19	1.458,68	—	—
SIXY Discretionary SIXY Discretionary	SIXY -0,93%	2.375,15	-22,35	-0,93%	—	2.397,50	2.395,03	2.412,01	2.370,64	—	—

RARE:BMV

Ultragenyx Pharmaceutical Inc

1.150,56 MXN

0,00%

(0,00) 1G

16 ott, 13:57:47 GMT-6 · MXN

Tutti i simboli

YTD

MAX

	Simbolo	Prezzo	Cambio	% di cambio

Generazione degli approfondimenti principali per RARE in corso…

Cap. mercato

2,41 Mld

Volume

0,00

Max 52 sett.

1.150,56 MXN

Min 52 sett.

1.150,56 MXN

N. di dipendenti

Azioni correlate

Intellia Therapeutics Inc

13,72 USD

+3,43%

RAPP

Rapport Therapeutics Inc

Articoli giornalistici

Da fonti sul web

Reuters

27 minuti fa

Wall St falls as Middle East tensions spark fresh jitters

ChartMill

36 minuti fa

Let's have a look at the top gainers and losers in the middle of the day of today's session.

Benzinga

1 ora fa

Gold Falls Over 2%; US Factory Orders Rise In March

MarketBeat

1 ora fa

Carter Bankshares (NASDAQ:CARE) Sets New 1-Year High - Still a Buy?

Profilo

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases. Ultragenyx is based in Novato, CA and Brisbane, CA and has a presence in the Boston area, including a gene therapy plant under construction as of 2021. The company’s Latin American headquarters is located in Miami. Ultragenyx collaborates on product development with other companies including GeneTX, Kyowa Hakko Kirin, Mereo Biopharma and Daiichi Sankyo. Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and several others currently in clinical trials. The company also holds the non-US commercial rights to Regeneron’s evinacumab-dgnb, which is approved by the FDA and EMA. Wikipedia

Informazioni su Ultragenyx Pharmaceutical Inc

CEOEmil Kakkis

Dipendenti1,37K

Data di fondazione2010

SedeNovato, California, Stati Uniti

Settore-

Sito webultragenyx.com

Tutti i valori in USD	mar 2025	giu 2025	set 2025	dic 2025
Fatturato	139,29 Mln	166,50 Mln	159,93 Mln	207,28 Mln
Costo dei beni venduti	194,43 Mln	187,74 Mln	244,20 Mln	232,62 Mln
Costo del venduto	194,43 Mln	187,74 Mln	244,20 Mln	232,62 Mln
Spese di ricerca e sviluppo	-	-	-	-
Spese totali per ricerca e sviluppo	-	-	-	-
Spese di vendita, generali e amministrative	87,80 Mln	86,65 Mln	86,62 Mln	87,94 Mln
Spese operative	87,80 Mln	86,65 Mln	86,62 Mln	87,94 Mln
Spese operative totali	282,23 Mln	274,38 Mln	330,82 Mln	320,56 Mln
Reddito operativo	-142,94 Mln	-107,89 Mln	-170,89 Mln	-113,28 Mln
Altri redditi non operativi	837,00K	2,14 Mln	-1,04 Mln	-934,00K
EBT inclusi elementi straordinari	-149,77 Mln	-114,00 Mln	-179,54 Mln	-127,69 Mln
EBT esclusi elementi straordinari	-149,61 Mln	-114,00 Mln	-180,22 Mln	-127,17 Mln
Spese per imposte sul reddito	1,31 Mln	947,00K	873,00K	870,00K
Aliquota fiscale effettiva	-0,87%	-0,83%	-0,49%	-0,68%
Altre spese operative	-	-	-	-
Risultato netto	-151,08 Mln	-114,95 Mln	-180,41 Mln	-128,56 Mln
Margine di profitto netto	-108,46%	-69,04%	-112,81%	-62,02%
Utili per azione	-1,57	-1,17	-1,81	-1,29
Interessi e reddito da investimento	6,83 Mln	5,79 Mln	5,86 Mln	6,51 Mln
Interesse passivo	-14,34 Mln	-14,04 Mln	-14,15 Mln	-19,47 Mln
Interessi passivi netti	-7,51 Mln	-8,25 Mln	-8,28 Mln	-12,96 Mln
Addebiti per ammortamento e svalutazione	-	-	-	-
EBITDA	-133,95 Mln	-99,27 Mln	-162,28 Mln	-104,50 Mln
Utile o perdita derivante dalla vendita di asset	-	-	-	-

I contenuti creati con l'AI potrebbero contenere errori. Scopri di più

AssistenzaInvia feedbackPrivacy Termini Disclaimer

Google Finanza

Ricerca